PEDIATRICS Vol. 87 No. 1 January 1991, pp. 101-107
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Auten, R. L.
Right arrow Articles by Shapiro, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Auten, R. L.
Right arrow Articles by Shapiro, D. L.

Surfactant Treatment of Full-Term Newborns With Respiratory Failure

Richard L. Auten MD1, Robert H. Notter MD, PhD1, James W. Kendig MD1, Jonathan M. Davis MD1, and Donald L. Shapiro MD1

1 From the Department of Pediatrics (Neonatology), University of Rochester School of Medicine, Rochester, New York

Surfactant inactivation has been shown to be a significant factor in animal models of lung injury and may also be important in some forms of respiratory failure in full-term newborns. Fourteen full-term newborns with respiratory failure associated with pneumonia (7 patients) and meconium aspiration syndrome (7 patients) were treated with 90 mg/kg of a calf lung surfactant extract, given intratracheally up to every 6 hours for a maximum of four doses. The group mean fraction of inspired oxygen (Fi02) before treatment was 0.99 ± 0.01 SEM, and the mean airway pressure (MAP) was 14.6 ± 1.0 cm H2O. Patients showed significant improvement in oxygenation after initial surfactant treatment, with the arterial-alveolar oxygenation ratio (a/A ratio) rising from 0.09 ± 0.01 before surfactant treatment to 0.22 ± 0.05 by 15 minutes (P = .03) and remaining improved for 6 hours. The oxygenation index, incorporating MAP as well as oxygen variables, also improved significantly from 26.2 ± 3.1 to 11.2 ± 1.7 at 15 minutes (P < .001), with improvement sustained for more than 6 hours. Chest radiographs were blindly scored from 0 (normal) to 5 (severe opacification), and these improved with marginal significance after initial surfactant treatment (from 2.9 ± 0.2 to 2.5 ± 0.2, P = .05). Eight patients subsequently met retreatment criteria (Fi02 ge 0.5 and MAP ge 7 cm H2O) and received a second surfactant dose, with a/A ratio rising from 0.124 ± 0.02 before treatment to 0.26 ± 0.07 after 45 minutes (P = .03) and remaining improved for more than 4 hours; the oxygenation index was also significantly improved over similar times by the second surfactant dose. Six patients received a third surfactant dose, with no increase in a/A ratio and a less prominent improvement in oxygenation index. There were no significant improvements in oxygenation in the three patients who received a fourth surfactant dose. Of the 14 patients treated, none died, required extracorporeal membrane oxygenation, had tension pneumothorax after study entry, required oxygen supplementation for more than 14 days, or required oxygen supplementation at discharge. These findings suggest that surfactant supplementation may provide therapeutic benefits for newborns with respiratory failure due to pneumonia or meconium aspiration and that expanded controlled trials of this therapy are indicated.

Key Words: surfactant therapy • full-term newborns • respiratory failure • surfactant inhibition • lung injury

Submitted on June 14, 1990
Accepted on September 5, 1990




This article has been cited by other articles:


Home page
 PediatricsHome page
W. A. Engle and and the Committee on Fetus and Newborn
Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate
Pediatrics, February 1, 2008; 121(2): 419 - 432.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
T. P. Stevens and R. A. Sinkin
Surfactant Replacement Therapy
Chest, May 1, 2007; 131(5): 1577 - 1582.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Z. Wang, A. Foye, Y. Chang, P. R. Chess, T. W. Wright, S. Bhagwat, F. Gigliotti, and R. H. Notter
Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro
Am J Physiol Lung Cell Mol Physiol, June 1, 2005; 288(6): L1124 - L1131.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
O. Flidel-Rimon and E. S. Shinwell
Respiratory Distress in the Term and Near-term Infant
NeoReviews, June 1, 2005; 6(6): e289 - e297.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
B. A. Davidson, P. R Knight, Z. Wang, P. R. Chess, B. A. Holm, T. A. Russo, A. Hutson, and R. H. Notter
Surfactant alterations in acute inflammatory lung injury from aspiration of acid and gastric particulates
Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L699 - L708.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. R. Hintz, D. M. Suttner, A. M. Sheehan, W. D. Rhine, and K. P. Van Meurs
Decreased Use of Neonatal Extracorporeal Membrane Oxygenation (ECMO): How New Treatment Modalities Have Affected ECMO Utilization
Pediatrics, December 1, 2000; 106(6): 1339 - 1343.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. ALMAAS, B. ROBERTSON, B. LINDERHOLM, E. LUNDBERG, O. D. SAUGSTAD, and A. MOEN
Reversal of Meconium Inhibition of Pulmonary Surfactant by Ferric Chloride, Copper Chloride, and Acetic Acid
Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1789 - 1794.
[Abstract] [Full Text]

Home page
 PediatricsHome page
E. Herting, O. Gefeller, M. Land, L. van Sonderen, K. Harms, B. Robertson, and Members of the Collaborative European Multicenter
Surfactant Treatment of Neonates With Respiratory Failure and Group B Streptococcal Infection
Pediatrics, November 1, 2000; 106(5): 957 - 964.
[Abstract] [Full Text]

Home page
 PediatricsHome page
A. H. Jobe
Commentary on Surfactant Treatment of Neonates With Respiratory Failure and Group B Streptococcal Infection
Pediatrics, November 1, 2000; 106(5): 1135 - 1135.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. HERTING, X. GAN, P. RAUPRICH, C. JARSTRAND, and B. ROBERTSON
Combined Treatment with Surfactant and Specific Immunoglobulin Reduces Bacterial Proliferation in Experimental Neonatal Group B Streptococcal Pneumonia
Am. J. Respir. Crit. Care Med., June 1, 1999; 159(6): 1862 - 1867.
[Abstract] [Full Text]

Home page
 PediatricsHome page
B. C. C. Lam, F. FHKCP, and C. Y. Yeung
Surfactant Lavage for Meconium Aspiration Syndrome: A Pilot Study
Pediatrics, May 1, 1999; 103(5): 1014 - 1018.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
T. F. Fok, M. Al-Essa, M. Dolovich, F. Rasid, and H. Kirpalani
Nebulisation of surfactants in an animal model of neonatal respiratory distress
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 1998; 78(1): 3F - 9.
[Abstract] [Full Text]

Home page
 PediatricsHome page
G. M. Cleary, M. J. Antunes, D. A. Ciesielka, S. T. Higgins, A. R. Spitzer, and A. Chander
Exudative Lung Injury Is Associated With Decreased Levels of Surfactant Proteins in a Rat Model of Meconium Aspiration
Pediatrics, December 1, 1997; 100(6): 998 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
E. Herting, B. Sun, C. Jarstrand, T. Curstedt, and B. Robertson
Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 1997; 76(1): 3F - 8.
[Abstract] [Full Text]

Home page
 NEJMHome page
A. H. Jobe
Pulmonary Surfactant Therapy
N. Engl. J. Med., March 25, 1993; 328(12): 861 - 868.
[Full Text]